Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Future PLC Share Issue/Capital Change 2019

Apr 1, 2019

4787_rns_2019-04-01_47181ac3-2724-45cf-84b0-dca58c214c17.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5548U

Future PLC

01 April 2019

THIS ANNOUNCEMENT DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE BASIS FOR ANY OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SHARES OR OTHER SECURITIES IN THE COMPANY NOR SHALL IT FORM THE BASIS FOR ANY CONTRACT OR COMMITMENT WHATSOEVER.

1 April 2019

Future plc

Transfer to a Premium Listing

Future plc is pleased to announce the approval by the Financial Conduct Authority of the transfer of the listing category of all of its ordinary shares from a Standard Listing (shares) to a Premium Listing (commercial company) on the Official List of the Financial Conduct Authority in accordance with Listing Rule 5.4A of the Listing Rules (the "Transfer"). The Transfer will take effect at 8.00 a.m. today.

Enquiries: 

Future plc via Instinctif Partners
Zillah Byng-Thorne, Chief Executive Officer

Penny Ladkin-Brand, Chief Financial Officer
Numis Securities Limited (Sole Sponsor and Joint Broker to Future) 020 7260 1000
Nick Westlake, Mark Lander, Hugo Rubinstein
Nplus1 Singer Capital Markets Limited (Joint Broker to Future) 020 7496 3000
Mark Taylor, James White
Instinctif Partners 020 7457 2077
Kay Larsen, Chantal Woolcock

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

MSCEAKDNAANNEFF